Arrival study (AstraZeneca) - open for inclusion
A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for Tezepelumab-treated Patients with Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission
Main inclusion criteria
- severe asthma diagnosis:
- FEV1 > 12% reversibility OR
- FEV1 ≥ 400mL variability OR
- Positive challenge test
- FEV1 op screening > 60%
- high dose ICS + LABA
- history of ≥ 1 asthma exacerbation within 12 months
- no chronic oral corticosteroids use
Contact
anja.delporte@uzgent.be, tel. 09 332 02 28
Airlympus study (Sanofi) - open for inclusion
A randomized, phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to investigate the efficacy, safety, and tolerability of subcutaneous lunsekimig in adult participants with high risk asthma who are not currently eligible for biologic treatment (ACT18301)
Main inclusion criteria
- FEV1 ≥40%
- Reversibility of at least 12% and 200 mL within 5 years
- ≥1 asthma exacerbation in the year prior to Screening , with at least 1 exacerbation occurring while on treatment with either:
- (1) maintenance ICS at a dose of ≤500 μg/day of fluticasone propionate, ≤800 μg/day of budesonide, or comparable ICS dosage, with or without LABA; or
- (2) low-dose budesonide/formoterol reliever therapy, taken as needed
- FeNO levels ≥50 ppb at Screening and FeNO levels ≥50 ppb at Baseline
- Blood total eosinophil count ≥300 cells/μL at Screening
or blood total eosinophil count ≥150 cells/μL at Screening and blood total
eosinophil count ≥300 cells/μL documented within the 12 months prior to Visit 1 - No systemic steroids, except for the treatment of asthma exacerbations
Contact
benedicte.demeyere@uzgent.be, tel. 09 332 28 19
3TR-ABC (academisch) - open for inclusion
A part of the 3TR (Taxonomy, Treatment, Targets and Remission) Consortium for the identification of molecular mechanisms of non-response to treatment, relapses, and remission in autoimmune, inflammatory, and allergic conditions
Main inclusion criteria
- severe asthma
- eligible to receive biological treatment
Contact
anja.delporte@uzgent.be, tel. 09 332 02 28
BSAR (academisch) - open for inclusion
Belgian Severe Asthma Registry
Main inclusion criteria
- severe asthma
Contact
anja.delporte@uzgent.be, tel. 09 332 02 28
Predictumab 1.0 (UCL - academisch) - closed for inclusion
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma
Contact
benedicte.demeyere@uzgent.be, tel. 09 332 28 19
Pfizer C4531029 - open for inclusion Q4 2025
A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the efficacy and safety of PF-07275315 in adult participants with inadequately controlled moderate-to-severe asthma.
Main inclusion criteria
- Moderate to severe asthma
- 18 - 70 years
- At least one asthma exacerbation
- FEV1 ≥30% to <80%
- Reversibility 12% and 200 ml at screening
Contact
anja.delporte@uzgent.be, tel. 09 332 02 28